JP2008503515A5 - - Google Patents

Download PDF

Info

Publication number
JP2008503515A5
JP2008503515A5 JP2007517147A JP2007517147A JP2008503515A5 JP 2008503515 A5 JP2008503515 A5 JP 2008503515A5 JP 2007517147 A JP2007517147 A JP 2007517147A JP 2007517147 A JP2007517147 A JP 2007517147A JP 2008503515 A5 JP2008503515 A5 JP 2008503515A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
compound
aryl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007517147A
Other languages
English (en)
Japanese (ja)
Other versions
JP5102021B2 (ja
JP2008503515A (ja
Filing date
Publication date
Priority claimed from DE102004029784A external-priority patent/DE102004029784A1/de
Application filed filed Critical
Publication of JP2008503515A publication Critical patent/JP2008503515A/ja
Publication of JP2008503515A5 publication Critical patent/JP2008503515A5/ja
Application granted granted Critical
Publication of JP5102021B2 publication Critical patent/JP5102021B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007517147A 2004-06-21 2005-06-15 新規2−ベンジルアミノジヒドロプテリジノン、それらを製造する方法及び薬剤としてのそれらの使用 Expired - Lifetime JP5102021B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004029784.3 2004-06-21
DE102004029784A DE102004029784A1 (de) 2004-06-21 2004-06-21 Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
PCT/EP2005/006404 WO2005123736A1 (de) 2004-06-21 2005-06-15 Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
JP2008503515A JP2008503515A (ja) 2008-02-07
JP2008503515A5 true JP2008503515A5 (cg-RX-API-DMAC7.html) 2008-07-31
JP5102021B2 JP5102021B2 (ja) 2012-12-19

Family

ID=35149569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007517147A Expired - Lifetime JP5102021B2 (ja) 2004-06-21 2005-06-15 新規2−ベンジルアミノジヒドロプテリジノン、それらを製造する方法及び薬剤としてのそれらの使用

Country Status (8)

Country Link
US (2) US20060004014A1 (cg-RX-API-DMAC7.html)
EP (1) EP1761536B1 (cg-RX-API-DMAC7.html)
JP (1) JP5102021B2 (cg-RX-API-DMAC7.html)
AT (1) ATE382049T1 (cg-RX-API-DMAC7.html)
CA (1) CA2571293C (cg-RX-API-DMAC7.html)
DE (2) DE102004029784A1 (cg-RX-API-DMAC7.html)
ES (1) ES2297724T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005123736A1 (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
NZ570530A (en) 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
JP5313875B2 (ja) 2006-04-12 2013-10-09 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患の処置のためのタンパク質キナーゼplk1の阻害剤として有用な4,5−ジヒドロ−[1,2,4]トリアゾロ[4,3−f]プテリジン
CN101484457B (zh) * 2006-04-12 2014-09-03 弗特克斯药品有限公司 作为用于治疗增殖病症的蛋白激酶PLK1抑制剂的4,5-二氢-[1,2,4]三唑并[4,3-f]蝶啶
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX337906B (es) * 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
CA2695406A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
WO2009023269A2 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2112152A1 (en) * 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
KR20110033239A (ko) * 2008-06-23 2011-03-30 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제
CN102076690A (zh) * 2008-06-23 2011-05-25 维泰克斯制药公司 蛋白激酶抑制剂
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
PL2442809T3 (pl) 2009-06-17 2017-02-28 Vertex Pharmaceuticals Incorporated Inhibitory replikacji wirusów grypy
JP5763077B2 (ja) 2009-09-14 2015-08-12 ギリアード サイエンシーズ, インコーポレイテッド トール様受容体のモジュレーター
JP2013512860A (ja) 2009-09-25 2013-04-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピリミジン誘導体の調製方法
KR20120094920A (ko) 2009-09-25 2012-08-27 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
CN106117213B (zh) 2009-10-26 2022-03-18 西格诺药品有限公司 杂芳基化合物及其合成和纯化方法
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
SG183155A1 (en) * 2010-02-03 2012-09-27 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
PH12014500869A1 (en) 2011-10-19 2014-06-30 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
US9351974B2 (en) 2011-11-10 2016-05-31 OSI Pharmaceuticals, LLC Substituted pteridinones for the treatment of cancer
KR102040997B1 (ko) 2011-12-02 2019-11-27 시그날 파마소티칼 엘엘씨 7-(6-(2-히드록시프로판-2-일)피리딘-3-일)-1-((트랜스)-4-메톡시시클로헥실)-3,4-디히드로피라지노[2,3-b]피라진-2(1H)-온, 그의 고체 형태의 제약 조성물 및 그의 사용 방법
TWI615143B (zh) 2012-02-24 2018-02-21 標誌製藥公司 使用tor激酶抑制劑組合療法以治療癌症之方法
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP2016505041A (ja) 2013-01-16 2016-02-18 シグナル ファーマシューティカルズ,エルエルシー 置換型ピロロピリミジン化合物、その組成物、およびこれらを用いた治療方法
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
CN105377260B (zh) 2013-04-17 2020-06-12 西格诺药品有限公司 二氢吡嗪并-吡嗪类化合物在制备治疗癌症的药物中的应用
JP6382947B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー 前立腺癌を治療するためのジヒドロピラジノ−ピラジン化合物及びアンドロゲン受容体アンタゴニストを含む組合せ療法
ES2744198T3 (es) 2013-04-17 2020-02-24 Signal Pharm Llc Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona
KR102271344B1 (ko) 2013-04-17 2021-07-01 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
WO2014193912A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ, インコーポレイテッド Hivを治療するためのトール様受容体の調節因子
US9623028B2 (en) 2014-07-14 2017-04-18 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターを調製する方法
KR20190125537A (ko) 2014-09-16 2019-11-06 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체 조정제의 고체 형태
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EA202090103A1 (ru) 2017-06-22 2020-04-24 Селджин Корпорейшн Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b
CA3097774A1 (en) * 2018-04-24 2019-10-31 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8303657A (nl) 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
FR2645152B1 (fr) 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
CA2029651C (en) 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
TW274550B (cg-RX-API-DMAC7.html) 1992-09-26 1996-04-21 Hoechst Ag
CO4410191A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AU5814596A (en) 1995-05-19 1996-11-29 Novartis Ag Process for the catalytic hydrogenation of aromatic nitro compounds
US5698556A (en) 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
PL194074B1 (pl) 1996-09-23 2007-04-30 Lilly Co Eli Polimorf Dihydrat D olanzapiny i preparat farmaceutyczny zawierający Dihydrat D olanzapiny
IL140868A0 (en) 1998-08-11 2002-02-10 Pfizer Prod Inc Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors
EE200200140A (et) 1999-09-15 2003-04-15 Warner-Lambert Company Pteridinoonid kui kinaasi inhibiitorid
JP2003528101A (ja) 2000-03-06 2003-09-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 5−アルキルピリド[2,3−d]ピリミジンチロシンキナーゼ阻害剤
DE10018783A1 (de) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de) 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2003020722A1 (de) 2001-09-04 2003-03-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1312365A1 (de) * 2001-11-20 2003-05-21 Jenapharm GmbH & Co. KG Pteridinone zur Behandlung der erektilen Dysfunktion
KR20040075004A (ko) 2001-12-14 2004-08-26 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 비폴리펩티드 고리에이엠피 레벨 모듈레이터를 이용한배란 유도 방법
PL372890A1 (en) 2002-05-03 2005-08-08 Schering Aktiengesellschaft Thiazolidinones and the use thereof as polo-like kinase inhibitors
AU2003265348B2 (en) 2002-08-08 2007-08-16 Smithkline Beecham Corporation Thiophene compounds
RS52386B (sr) 2003-02-26 2013-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg. Dihidropteridinoni, postupak za njihovo pripremanje i njihova primena kao leka
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
MXPA05008526A (es) 2003-03-26 2005-10-20 Wyeth Corp Metodos y composicion inmunogenica.
CA2522158C (en) 2003-04-14 2018-03-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
WO2005067935A1 (de) 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004002557A1 (de) 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
JP2008510771A (ja) 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
JP2009503014A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療におけるジヒドロプテリジノン
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CA2695406A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative

Similar Documents

Publication Publication Date Title
JP2008503515A5 (cg-RX-API-DMAC7.html)
JP2008506644A5 (cg-RX-API-DMAC7.html)
JP2008510770A5 (cg-RX-API-DMAC7.html)
JP2019104748A5 (cg-RX-API-DMAC7.html)
JP2008510771A5 (cg-RX-API-DMAC7.html)
JP2004516314A5 (cg-RX-API-DMAC7.html)
JP2008510691A5 (cg-RX-API-DMAC7.html)
JP2006182786A5 (cg-RX-API-DMAC7.html)
JP2009536620A5 (cg-RX-API-DMAC7.html)
JP2015537020A5 (cg-RX-API-DMAC7.html)
JP2013510120A5 (cg-RX-API-DMAC7.html)
JP2016518437A5 (cg-RX-API-DMAC7.html)
JP2015024998A5 (cg-RX-API-DMAC7.html)
JP2009534405A5 (cg-RX-API-DMAC7.html)
JP2009511508A5 (cg-RX-API-DMAC7.html)
JP2015522650A5 (cg-RX-API-DMAC7.html)
JP2011037841A5 (cg-RX-API-DMAC7.html)
JP2008510828A5 (cg-RX-API-DMAC7.html)
JP2010155827A5 (cg-RX-API-DMAC7.html)
WO2002090332A3 (en) Novel aeylheteroalkylaminε derivatives
JP2015526453A5 (cg-RX-API-DMAC7.html)
SE0203304D0 (sv) Novel Coumpounds
JP2009520695A5 (cg-RX-API-DMAC7.html)
JP2016514727A5 (cg-RX-API-DMAC7.html)
JP2004523478A5 (cg-RX-API-DMAC7.html)